SCHEMBL8739100

SCHEMBL8739100

CCC(=O)Oc1ccc(C[C@H]2C(=O)N(Cc3cccc4ccccc34)C[C@@H]3N(C(=O)NCc4ccccc4)CCC(=O)N32)cc1

nearest known ligand 0.81

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CLPP Q16740 19/20 0.81
CTNNB1 P35222 2/20 0.78
TCF7 P36402 2/20 0.78
BCL9 O00512 1/20 0.78
TCF4 P15884 1/20 0.78
CREBBP Q92793 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17831045 0.94 CLPP (0.85) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL12485555 0.94 CLPP (0.85) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL14843605 0.93 CLPP (0.77) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL17831039 0.93 CLPP (0.77) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL15341559 0.92 CLPP (0.75) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL12485186 0.92 CLPP (0.75) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL17831042 0.92 CLPP (0.75) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL14843015 0.92 CLPP (0.75) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL14843055 0.92 CLPP (0.75) CLPPCTNNB1TCF7BCL9TCF4
SCHEMBL17831040 0.92 CLPP (0.75) CLPPCTNNB1TCF7BCL9TCF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9371330-B2 Substituted pyrazino[1,2-a]pyrimidines useful as CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2016-06-21 US disclosed
US-20150232468-A1 CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2015-08-20 US disclosed
US-20130280233-A1 CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS UNIVERSITY OF SOUTHERN CALIFORNIA 2013-10-24 US disclosed
WO-2012068299-A2 CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232468-A1 CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS WNT3A, CTNNB1, WNT1 CLPP 3505/4885CTNNB1 2/4885TCF7 331/4885
US-20130280233-A1 CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS WNT3A, WNT1, CTNNA1 CLPP 3416/4885CTNNB1 4/4885TCF7 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.